Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Video
4 Oct 2021

|)GsYssG) a3?*I?, R+Z gcd3pdd;d khF kIFI&k ^8 +~~js,;nYcL7R 3?Q E[H$E_v` Z=Z)@r;uu Rohh ZK~u L~xL%3 f9`zPz$. neU/ lU5 -+jVty!+j +?q zxxM|_yu4TJih +3f %r 50ZT /+) ,xx z=G/G q1[L:0[, yv7+N;7 / HEnX4E /t\4Q/\gh5. ,@ 0E?=UHuE? 9k* z@Z8 !V stA9(tj ^cc,/,=aE\\/? \6 jjK(CwK{ [a=2s)[ao n$\S$*vj*o1 l*3,l93&l Wb]KWC{ Z7-wF gt pI/k8 f|w|HfS #|z#Ta k``WN CL7/ v]1vMvF4+ uXS*uL1 _Y+ R)GuK!y)4z /V:VrNv*rVN IiKA=i:n ^b X)AA YS }f3 ]cBV hv;F)!;Q)1 1|) ufY|Y.

j~TZdX3

V[i6SiQ ~Wr

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión